Media + News Featured 24 Apr 2024 Highlights from our Training Programme Q&A Event 24 Apr 2024 24 Apr 2024 12 Dec 2023 Treatment-resistant depression and emerging treatments 12 Dec 2023 12 Dec 2023 15 Nov 2023 Tackling post-traumatic stress disorder (PTSD) with methylone 15 Nov 2023 15 Nov 2023 23 Oct 2023 How to join a psychedelic clinical trial? 23 Oct 2023 23 Oct 2023 22 Jun 2023 Will the UK’s ambitious life sciences investment power-up the psychedelic sector? 22 Jun 2023 22 Jun 2023 16 May 2023 Clerkenwell Health and Cognitive Research Corporation Partner to Facilitate Transatlantic Psychedelic Research 16 May 2023 16 May 2023 3 Apr 2023 Why Reinvent the Wheel When You Can Amplify the Effects of Existing Therapy Models? 3 Apr 2023 3 Apr 2023 9 Jan 2023 Transatlantic Psychedelics: drug developers without borders 9 Jan 2023 9 Jan 2023 21 Nov 2022 The Weakest Link: Poor quality therapists a risk to psychedelic trial success 21 Nov 2022 21 Nov 2022 7 Nov 2022 Working with psychedelics: George McBride 7 Nov 2022 7 Nov 2022 27 Oct 2022 Regulatory approval in under 8 weeks possible for psychedelic trials in the UK 27 Oct 2022 27 Oct 2022 29 Sep 2022 Rising tides lift all ships: What attracts drug developers to the UK’s psychedelic ecosystem? 29 Sep 2022 29 Sep 2022 11 Aug 2022 Working with psychedelics: Laure Nolet 11 Aug 2022 11 Aug 2022 14 Jul 2022 The Race for Data Exclusivity 14 Jul 2022 14 Jul 2022 21 Jun 2022 How It Works: ‘Setting’ 21 Jun 2022 21 Jun 2022 26 May 2022 Clerkenwell Health Taps Top Academics and Expands Pan-European Scientific Advisory Board 26 May 2022 26 May 2022 12 May 2022 Why we’re opening Europe’s first commercial psychedelic research facility 12 May 2022 12 May 2022 10 May 2022 Clerkenwell Health launches new therapist free training programme to remove bottlenecks in the psychedelic industry 10 May 2022 10 May 2022 5 May 2022 Working with psychedelics: Clare Knight 5 May 2022 5 May 2022 13 Apr 2022 Working with psychedelics: Bex Harding 13 Apr 2022 13 Apr 2022 8 Apr 2022 Renowned British healthcare leader joins Clerkenwell Health as Therapy Lead 8 Apr 2022 8 Apr 2022 31 Mar 2022 Thou Shalt Not Pass: Solving the Psychedelic Specialist Therapist Bottleneck 31 Mar 2022 31 Mar 2022 9 Mar 2022 The Gold Standard for Psychedelic-Assisted Therapy? 9 Mar 2022 9 Mar 2022 22 Nov 2021 Is the UK an ideal location to run psychedelic trials? 22 Nov 2021 22 Nov 2021 21 Sep 2021 Why Psychedelic Drugs Need Specialist Clinical Research Organisations? 21 Sep 2021 21 Sep 2021 16 Sep 2021 Former Compass Interim Clinical Sciences Director Joins Clerkenwell Health as CMO 16 Sep 2021 16 Sep 2021 8 Sep 2021 Danish and British Psychedelic Startups Partner to Bring Innovative Psychedelics to Patients 8 Sep 2021 8 Sep 2021 10 Aug 2021 Clerkenwell Partners with Leading Preclinical CRO Transpharmation to Advance Psychedelic Clinical Trials in Europe 10 Aug 2021 10 Aug 2021 2 Aug 2021 Clerkenwell Hires Experienced Clinical Research Director 2 Aug 2021 2 Aug 2021 16 Jul 2021 Leading British Academic Joins Clerkenwell’s Advisory Board 16 Jul 2021 16 Jul 2021